Yufeng Hong
YOU?
Author Swipe
View article: Supplementary Table 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Supplementary Table 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Table S1. Surface BCMA expression level and corresponding STI-8811 cytotoxicity EC50 in 16 tumor cell lines
View article: Supplementary Figure 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Supplementary Figure 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Figure S1. Quantitative STI-8811 and J6M0-mc-MMAF internalization as measured by flow cytometry in RPMI8226 cell line expressing moderate BCMA levels (n = 2). Signal is measured following protease-K treatment to remove membrane bound antib…
View article: Supplementary Figure 2 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Supplementary Figure 2 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Figure S2. Long-term tumor suppression study of repeat dosing of STI-8811 in NCI-H929 s.c. xenograft model. SCID-Beige (n = 7) mice were treated i.v. with 4 doses of indicated molecules at biweekly regimen. Data represent mean ± SD
View article: Figure 5 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Figure 5 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Tumor suppression study of STI-8811 in xenograft mouse models. A, Dose escalation study of STI-8811 in NCI-H929 s.c. xenograft tumor models. Mice (n = 7) were treated i.v. with single dose of STI-8811 or PBS as a control. All data are repr…
View article: Supplementary Figure 2 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Supplementary Figure 2 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Figure S2. Long-term tumor suppression study of repeat dosing of STI-8811 in NCI-H929 s.c. xenograft model. SCID-Beige (n = 7) mice were treated i.v. with 4 doses of indicated molecules at biweekly regimen. Data represent mean ± SD
View article: Figure 4 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Figure 4 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Effect of sBCMA on the cytotoxic activity of STI-8811 and J6M0-mc-MMAF. A, Cell viability of NCI-H929 (left) and OPM-2 (right) after treatment with serial dilutions of STI-8811 and J6M0-mc-MMAF in the absence of sBCMA (n = 3). Arrows repre…
View article: Figure 2 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Figure 2 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Cytotoxic activity of STI-8811 on multiple myeloma cell lines and correlation with BCMA surface expression. A, Cytotoxic activity of STI-8811 in indicated multiple myeloma cell lines after 120 hours of incubation (n = 3–9). Data are repres…
View article: Supplementary Figure 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Supplementary Figure 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Figure S1. Quantitative STI-8811 and J6M0-mc-MMAF internalization as measured by flow cytometry in RPMI8226 cell line expressing moderate BCMA levels (n = 2). Signal is measured following protease-K treatment to remove membrane bound antib…
View article: Figure 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Figure 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
STI-8811 structure, binding, and internalization capacity in BCMA-expressing tumor cell lines. A, Structure and analytical data of STI-8811 showing cysteine rebridging conjugation, cleavable Gly5 linker, and Duo5 payload. B, BCMA surface e…
View article: Data from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Data from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Treatment for patients with multiple myeloma has experienced rapid development and improvement in recent years; however, patients continue to experience relapse, and multiple myeloma remains largely incurable. B-cell maturation antigen (BC…
View article: Figure 6 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Figure 6 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Serum stability and PK studies. A, PK curves of STI-8811 and STI-1260 in SCID beige mice following single-dose 8 mg/kg i.v. administration. B, PK curves of STI-8811 and STI-1260 in cynomolgus monkeys with single-dose i.v. administration. C…
View article: Supplementary Table 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Supplementary Table 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Table S1. Surface BCMA expression level and corresponding STI-8811 cytotoxicity EC50 in 16 tumor cell lines
View article: Figure 3 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Figure 3 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Mechanism-of-action of STI-8811. A, Cell-cycle assay in NCI-H929 (left) and K562 (right) cell lines following 72 hours of treatment at 1 nmol/L. Bar height showing the percentage of cell population in each cell-cycle phase (n = 2). B, Casp…
View article: Table 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Table 1 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Serum stability of STI-8811 in rat, cynomolgus monkey, and human serum determined by the percentage of payload release over 21 days (n = 3)
View article: Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma
Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma Open
Treatment for patients with multiple myeloma has experienced rapid development and improvement in recent years; however, patients continue to experience relapse, and multiple myeloma remains largely incurable. B-cell maturation antigen (BC…
View article: Coordination of Nanoconjugation with an Antigen/Antibody for Efficient Detection of Gynecological Tumors
Coordination of Nanoconjugation with an Antigen/Antibody for Efficient Detection of Gynecological Tumors Open
Cervical, ovarian, and endometrial cancers are common in the female reproductive system. Cervical cancer starts from the cervix, while ovarian cancer develops when abnormal cells grow in the ovary. Endometrial or uterine cancer starts from…
View article: Outcome of high-intensity focused ultrasound and uterine artery embolization in the treatment and management of cesarean scar pregnancy
Outcome of high-intensity focused ultrasound and uterine artery embolization in the treatment and management of cesarean scar pregnancy Open
The aim of the study was to compare the efficacy and safety between high-intensity focused ultrasound (HIFU) treatment and uterine artery embolization (UAE) treatment; we retrospectively analyzed 152 cases with cesarean scar pregnancy (CSP…